Wine flavonoids protect against LDL oxidation and atherosclerosis

Annals of the New York Academy of Sciences

Volumn 957, Issue , 2002, Pages 146-161

  Aviram, Michael ^a,b   Fuhrman, Bianca ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Aggregated LDL; Antioxidants; Atherosclerosis; Flavonoids; LDL; Lipid peroxidation; Oxidized LDL; Paraoxonase; Polyphenols; Red wine

Indexed keywords

ALCOHOL; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; COPPER ION; FLAVANOL DERIVATIVE; FLAVONOID; LOW DENSITY LIPOPROTEIN; QUERCETIN; SCAVENGER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; BIOSYNTHESIS; CONFERENCE PAPER; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; FOAM CELL; HEART PROTECTION; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MOUSE; NONHUMAN; WINE;

ANIMALIA; VITIS SP.;

EID: 0036296295     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb02913.x     Document Type: Conference Paper

References (91)

1. Arterial foam cells with distinctive immuno-morphologic and histochemical features of macrophages
2. The role of monocytes in atherogenesis
3. Regulation of the mevalonate pathway
4. A receptor-mediated pathway for cholesterol homeostasis
5. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity
6. Modified forms of low density lipoprotein and atherosclerosis
7. Beyond cholesterol: Modifications of lipoproteins and increased atherogenicity
8. The role of oxidized low density lipoprotein in atherogenesis
9. Low density lipoprotein oxidation and its pathobiological significance
10. The role of oxidized lipoproteins in atherosclerosis
11. Oxidative modification of low density lipoprotein and atherosclerosis
12. Role of oxidized low density lipoprotein in atherogenesis
13. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis and the antiatherogenicity of antioxidants
14. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase
15. Oxidized low-density lipoprotein, a two-faced janus in coronary artery disease?
16. The role of oxidized LDL in atherogenesis
17. Is oxidized low density lipoprotein present in vivo?
18. The contribution of the macrophage receptor for oxidized LDL to its cellular uptake
19. Macrophage mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor
20. Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein
21. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids
22. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture
23. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor
24. LDL oxidation by arterial wall macrophages depends on the antioxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants
25. Iron induces lipid peroxidation in cultured macrophages, increases their ability to oxidatively modify LDL and affect their secretory properties
26. Increased uptake of low density lipoprotein (LDL) by oxidized macrophages is the result of enhanced LDL receptor activity and of progressive LDL oxidation
27. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study
28. Antioxidant effect of flavonoids
29. The relative antioxidant activities of plant-derived polyphenolic flavonoids
30. Polyphenolic flavonoids inhibit macrophage-mediated oxidation of LDL and attenuate atherogenesis
31. Polyphenols and flavonoids protect LDL against atherogenic modifications
32. Anti-atherogenicity of nutritional antioxidants
33. Flavonoids protect LDL from oxidation and attenuate atherosclerosis
34. Macrophage enrichment with the isoflavan glabridin inhibits NADPH oxidase-induced cell mediated oxidation of low density lipoprotein
35. Inhibition of glutathione reductase by flavonoids. A structure-activity study
36. Relative inhibitory potencies of flavonoids on 12-lipoxygenase of fish gill
37. Inhibition of mammalian 15-lipoxygenase-dependent lipid peroxidation in low density lipoprotein by quercetin and quercetin monoglucosides
38. Structure-antioxidant activity relationships of flavonoids and phenolic acids
39. Structural aspects of antioxidants activity of flavonoids
40. Wine alcohol, platelets and the French paradox for coronary heart disease
41. Wine as a biological fluid: History, production, and role in disease prevention
42. Content of potentially anticarcinogenic flavonoids of tea infusions, wines, and fruit juices
43. Inhibition of human low density lipoprotein oxidation by caffeic acid and other hydroxycinnamic acid derivatives
44. Phenolic content of various beverages determines the extent of inhibition of human serum and low density lipoprotein oxidation in vitro: Identification and mechanism of some cinnamic derivatives from red wine
45. Inhibition of human LDL oxidation by resveratrol
46. Flavonoids inhibit the oxidative modification of low density lipoproteins by macrophages
47. Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin
48. Plant flavonoids, especially tea flavonols, are powerful antioxidants using an in vitro model for heart disease
49. The inhibition of the oxidation of low density lipoprotein by (+)-catechin, a naturally occurring flavonoid
50. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants
51. Grape extract inhibits lipid peroxidation of human low density lipoprotein
52. Bioabsorption and in vivo antioxidant properties of grape extract BioVin: A human intervention study
53. Inhibition of human low density lipoprotein oxidation by flavonoids in red wine and grape juice
54. Inhibition of oxidation human low density lipoprotein by phenolic substances in red wine
55. Principal phenolic phytochemicals in selected Californian wines and their antioxidant activity in inhibiting oxidation of human low-density lipoproteins
56. Red wine and fractionated phenolic compounds prepared from red wine inhibit low density lipoprotein oxidation in vitro
57. White wine reduces the susceptibility of low density lipoprotein to oxidation
58. Beneficial effects of white wines
59. The polyphenolic content of fruit and vegetables and their antioxidant activities. What does a serving constitute?
60. Red wine inhibits the cell-mediated oxidation of LDL and HDL
61. Alcohol-free red wine enhances plasma antioxidant capacity in humans
62. Phenol antioxidant index: Comparative antioxidant effectiveness of red and white wines
63. Kinetic analysis of antioxidant capacity of wine
64. White wine with red wine-like properties: Increased extraction of grape skin polyphenols improves the antioxidant capacity of the derived white wine
65. Consumption of red wine with meals reduces the susceptibility of human plasma and LDL to undergo lipid peroxidation
66. Consumption of red wine polyphenols reduces the susceptibility of low density lipoproteins to oxidation in vivo
67. Non-alcoholic red wine extract and quercetin inhibit LDL oxidation without affecting plasma antioxidant vitamins and carotenoid concentrations
68. Red wine consumption does not affect oxidisability of low-density lipoproteins in volunteers
69. Ingestion of red wine significantly increases plasma phenolic acid concentrations but does not acutely affect ex-vivo lipoprotein oxidizability
70. Red wine consumption and inhibition of LDL oxidation
71. Survey of free and conjugated myricetin and quercetin content of red wines of different geographical origin
72. Clusters sun exposure and quercetin in Pinot noir grapes and wines
73. Reduced progression of atherosclerosis in the apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation
74. Red wine consumption inhibits LDL oxidation and aggregation in humans and in atherosclerotic mice
75. Paraoxonases biochemistry, genetics and relationship to plasma lipoproteins
76. Studies on human serum paraoxonase/arylesterase
77. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: A possible peroxidative role for paraoxonase
78. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
79. Does paraoxonase play a role in susceptibility to cardiovascular disease?
80. On the physiological role(s) of the paraoxonases
81. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus
82. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
83. Paraoxonase polymorphism MetLeu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
84. Lesion-derived low density lipoprotein and oxidized low density lipoprotein share a lability for aggregation, leading to enhanced macrophage degradation
85. Oxidation of low density lipoprotein leads to particle aggregation and altered macrophage recognition
86. Lipoprotein-proteoglycan complexes from injured rabbit aortas accelerate lipoprotein uptake by arterial smooth muscle cells
87. Interaction of LDL with human arterial proteoglycans stimulates its uptake by human monocyte-derived macrophages
88. Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E deficient mice
89. Lesioned low density lipoprotein in atherosclerotic apolipoprotein E-deficient transgenic mice and in humans is oxidized and aggregated
90. Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I
91. The specificity of proanthocyanidin - Protein interactions